Zobrazeno 1 - 10
of 154
pro vyhledávání: '"Adam J. Schoenfeld"'
Autor:
Pooja Middha, Rohit Thummalapalli, Michael J. Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam, Cosmin A. Bejan, Eduardo Cardenas, Christina J. Falcon, David M. Faleck, Princess Margaret Lung Group, Matthew A. Gubens, Scott Huntsman, Douglas B. Johnson, Linda Kachuri, Khaleeq Khan, Min Li, Christine M. Lovly, Megan H. Murray, Devalben Patel, Kristin Werking, Yaomin Xu, Luna Jia Zhan, Justin M. Balko, Geoffrey Liu, Melinda C. Aldrich, Adam J. Schoenfeld, Elad Ziv
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event of treatment with immune checkpoint inhibitors (ICI). We hypothesize that genetic susceptibility to Crohn’s disease (CD) and ulcerative colitis (UC) predisposes t
Externí odkaz:
https://doaj.org/article/46e01ed1d0cc4b39bd52631c3a872a9b
Autor:
Joao V. Alessi, Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Arielle Elkrief, Scott J. Rodig, Emily S. Lebow, Jordan E. Eicholz, Maria Thor, Andreas Rimner, Adam J. Schoenfeld, Jamie E. Chaft, Bruce E. Johnson, Daniel R. Gomez, Mark M. Awad, Narek Shaverdian
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and genomic factors associated with its efficacy remain poorly characte
Externí odkaz:
https://doaj.org/article/1cb0d71dba954b7a82afb042b77b3eda
Autor:
Kamrine E. Poels, Adam J. Schoenfeld, Alex Makhnin, Yosef Tobi, Yuli Wang, Heidie Frisco-Cabanos, Shaon Chakrabarti, Manli Shi, Chelsi Napoli, Thomas O. McDonald, Weiwei Tan, Aaron Hata, Scott L. Weinrich, Helena A. Yu, Franziska Michor
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Osimertinib and dacomitinib are approved as first-line treatment of EGFR-mutant NSCLC but resistance can arise. Here, the authors use a computational model to identify an optimal dosing schedule for osimertinib and dacomitinib combination therapy tha
Externí odkaz:
https://doaj.org/article/f560d9720b2540fab5539f7d8afa3e27
Autor:
Kamrine E. Poels, Adam J. Schoenfeld, Alex Makhnin, Yosef Tobi, Yuli Wang, Heidie Frisco-Cabanos, Shaon Chakrabarti, Manli Shi, Chelsi Napoli, Thomas O. McDonald, Weiwei Tan, Aaron Hata, Scott L. Weinrich, Helena A. Yu, Franziska Michor
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/0d2dddae1cc34582bd3de123927fce55
Autor:
Ziad, Bakouny, Chris, Labaki, Punita, Grover, Joy, Awosika, Shuchi, Gulati, Chih-Yuan, Hsu, Saif I, Alimohamed, Babar, Bashir, Stephanie, Berg, Mehmet A, Bilen, Daniel, Bowles, Cecilia, Castellano, Aakash, Desai, Arielle, Elkrief, Omar E, Eton, Leslie A, Fecher, Daniel, Flora, Matthew D, Galsky, Margaret E, Gatti-Mays, Alicia, Gesenhues, Michael J, Glover, Dharmesh, Gopalakrishnan, Shilpa, Gupta, Thorvardur R, Halfdanarson, Brandon, Hayes-Lattin, Mohamed, Hendawi, Emily, Hsu, Clara, Hwang, Roman, Jandarov, Chinmay, Jani, Douglas B, Johnson, Monika, Joshi, Hina, Khan, Shaheer A, Khan, Natalie, Knox, Vadim S, Koshkin, Amit A, Kulkarni, Daniel H, Kwon, Sara, Matar, Rana R, McKay, Sanjay, Mishra, Feras A, Moria, Amanda, Nizam, Nora L, Nock, Taylor K, Nonato, Justin, Panasci, Lauren, Pomerantz, Andrew J, Portuguese, Destie, Provenzano, Matthew, Puc, Yuan J, Rao, Terence D, Rhodes, Gregory J, Riely, Jacob J, Ripp, Andrea V, Rivera, Erika, Ruiz-Garcia, Andrew L, Schmidt, Adam J, Schoenfeld, Gary K, Schwartz, Sumit A, Shah, Justin, Shaya, Suki, Subbiah, Lisa M, Tachiki, Matthew D, Tucker, Melissa, Valdez-Reyes, Lisa B, Weissmann, Michael T, Wotman, Elizabeth M, Wulff-Burchfield, Zhuoer, Xie, Yuanchu James, Yang, Michael A, Thompson, Dimpy P, Shah, Jeremy L, Warner, Yu, Shyr, Toni K, Choueiri, Trisha M, Wise-Draper, Catherine, Stratton
Publikováno v:
JAMA oncology.
ImportanceCytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation.ObjectiveTo determine the association of baseline immunosup
Autor:
Joao V. Alessi, Arielle Elkrief, Biagio Ricciuti, Xinan Wang, Alessio Cortellini, Victor R. Vaz, Giuseppe Lamberti, Rosa L. Frias, Deepti Venkatraman, Claudia A.M. Fulgenzi, Federica Pecci, Gonzalo Recondo, Alessandro Di Federico, Adriana Barrichello, Hyesun Park, Mizuki Nishino, Grace M. Hambelton, Jacklynn V. Egger, Marc Ladanyi, Subba Digumarthy, Bruce E. Johnson, David C. Christiani, Xihong Lin, Justin F. Gainor, Jessica J. Lin, David J. Pinato, Adam J. Schoenfeld, Mark M. Awad
Publikováno v:
Journal of Thoracic Oncology. 18:731-743
Autor:
Biagio Ricciuti, Arielle Elkrief, Joao Alessi, Xinan Wang, Yvonne Li, Hersh Gupta, Daniel M. Muldoon, Arrien A. Bertram, Federica Pecci, Giuseppe Lamberti, Alessandro Di Federico, Adriana Barrichello, Victor R. Vaz, Malini Gandhi, Elinton Lee, Geoffrey I. Shapiro, Hyesun Park, Mizuki Nishino, James Lindsay, Kristen D. Felt, Bijaya Sharma, Andrew D. Cherniack, Scott Rodig, Daniel R. Gomez, Narek Shaverdian, Mehrdad Rakaee, Chaitanya Bandlamudi, Marc Ladanyi, Pasi A. Janne, Adam J. Schoenfeld, Lynette M. Sholl, Mark M. Awad, Michael L. Cheng
Publikováno v:
Clinical Cancer Research. :OF1-OF11
Purpose: ATM is the most commonly mutated DNA damage and repair gene in non–small cell lung cancer (NSCLC); however, limited characterization has been pursued. Experimental Design: Clinicopathologic, genomic, and treatment data were collected for 5
Autor:
Noura J. Choudhury, Antonio Marra, Jane S.Y. Sui, Jessica Flynn, Soo-Ryum Yang, Christina J. Falcon, Pier Selenica, Adam J. Schoenfeld, Natasha Rekhtman, Daniel Gomez, Michael F. Berger, Marc Ladanyi, Maria Arcila, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Glenn Heller, Jorge S. Reis-Filho, Helena A. Yu
Publikováno v:
Journal of Thoracic Oncology. 18:463-475
Preferred first-line treatment for patients with metastatic EGFR-mutant lung cancer is osimertinib, yet it is not known if patient outcomes may be improved by identifying and intervening upon molecular markers associated with therapeutic resistance.A
Autor:
Julie R. Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, Laszlo Urban, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Adam Pluzanski, Jacobus Burgers, Mauricio Mahave, Samreen Ahmed, Adam J. Schoenfeld, Luis G. Paz-Ares, Martin Reck, Hossein Borghaei, Kenneth J. O'Byrne, Ravi G. Gupta, Judith Bushong, Li Li, Steven I. Blum, Laura J. Eccles, Suresh S. Ramalingam
Publikováno v:
Journal of Clinical Oncology. 41:1200-1212
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non–small-cell lung cancer, regardless of tumor programmed death ligand 1
Autor:
Michael L. Cheng, Mark M. Awad, Lynette M. Sholl, Adam J. Schoenfeld, Pasi A. Janne, Marc Ladanyi, Chaitanya Bandlamudi, Mehrdad Rakaee, Narek Shaverdian, Daniel R. Gomez, Scott Rodig, Andrew D. Cherniack, Bijaya Sharma, Kristen D. Felt, James Lindsay, Mizuki Nishino, Hyesun Park, Geoffrey I. Shapiro, Elinton Lee, Malini Gandhi, Victor R. Vaz, Adriana Barrichello, Alessandro Di Federico, Giuseppe Lamberti, Federica Pecci, Arrien A. Bertram, Daniel M. Muldoon, Hersh Gupta, Yvonne Li, Xinan Wang, Joao Alessi, Arielle Elkrief, Biagio Ricciuti
Supplementary Figure 8. Oncoprint plot showing the distribution of the most commonly mutated genes in NSCLCs with complete ATM loss by IHC (ATMLOST), intact ATM expression (ATMINTACT), and ATM heterogeneous loss (ATMHET LOST) by IHC.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13741cbb04662f96d405a375d90c5505
https://doi.org/10.1158/1078-0432.22893749.v1
https://doi.org/10.1158/1078-0432.22893749.v1